Novo Nordisk advances its obesity pipeline by planning late-stage clinical trials for amycretin, a dual GLP-1 and amylin receptor agonist. Following promising phase 2 data indicating substantial weight loss, the program includes both injectable and oral options. This initiative underscores Novo’s commitment to innovative obesity treatments amid competitive market dynamics.